Olema Pharmaceuticals, Inc.
OLMA
$4.26
$0.051.19%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.74% | -0.51% | -11.19% | -24.71% | -23.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.53% | 40.16% | 25.88% | 1.77% | -1.89% |
| Operating Income | -35.53% | -40.16% | -25.88% | -1.77% | 1.89% |
| Income Before Tax | -33.95% | -27.71% | -12.69% | 9.73% | 7.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.95% | -27.71% | -12.69% | 9.73% | 7.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.95% | -27.71% | -12.69% | 9.73% | 7.76% |
| EBIT | -35.53% | -40.16% | -25.88% | -1.77% | 1.89% |
| EBITDA | -35.65% | -40.34% | -26.01% | -1.79% | 1.92% |
| EPS Basic | -2.29% | 5.80% | 14.48% | 26.44% | 17.51% |
| Normalized Basic EPS | -3.17% | 0.62% | 9.76% | 22.63% | 18.22% |
| EPS Diluted | -2.29% | 5.80% | 14.48% | 26.44% | 17.51% |
| Normalized Diluted EPS | -3.17% | 0.62% | 9.76% | 22.63% | 18.22% |
| Average Basic Shares Outstanding | 29.90% | 34.69% | 31.20% | 22.16% | 13.04% |
| Average Diluted Shares Outstanding | 29.90% | 34.69% | 31.20% | 22.16% | 13.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |